𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck

✍ Scribed by Sarah H. Landis; Iman A. El-Hariry; Myrthe P. P. van Herk-Sukel; Pieter van den Haak; Maryska L. G. Janssen-Heijnen; Fernie J. A. Penning-van Beest; Ron M. C. Herings

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
178 KB
Volume
34
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Limited data exist on the burden of comorbidity among patients with squamous cell head and neck cancer (SCCHN) before and during cancer treatment.

Methods

The precancer prevalence and incidence rates of 8 comorbid conditions were estimated among a population‐based cohort of 1499 patients with SCCHN in the Netherlands. Patients with cancer, treatments, and comorbidities were identified in the PHARMO Record Linkage System (RLS) using hospital admissions and/or dispensing codes. Prevalence proportions and incidence rates were also compared against a matched cancer‐free population.

Results

Cardiovascular (41%) and respiratory diseases (12%) were the most prevalent comorbidities. Incidence rates of most comorbidities were highest the first 6 months after cancer diagnosis and decreased over time. Patients receiving chemotherapy‐based treatment had significantly higher incidence rates of anemia and other malignant diseases.

Conclusions

High rates of acute and chronic comorbidity were observed; knowledge of comorbidity burden aids in establishing a benefit–risk profile for investigational SCCHN therapies. Β© 2011 Wiley Periodicals, Inc. Head Neck, 2012

πŸ“œ SIMILAR VOLUMES

Impact of comorbidity on outcome of youn
Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma
✍ Bhuvanesh Singh; Mahesh Bhaya; Marc Zimbler; Jordan Stern; J. Thomas Roland; Ric πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 3 views

Background. Comorbid conditions have a significant impact on the actuarial survival of patients with head and neck cancer. However, no studies have evaluated the impact of comorbidity on tumor-and treatment-specific outcomes. This study was performed to evaluate the impact of comorbidity, graded by

Efficacy of neck treatment in patients w
Efficacy of neck treatment in patients with head and neck squamous cell carcinoma
✍ Gabriela Buck; Pia Huguenin; Sandro J. Stoeckli πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the

The incidence of hypercalcemia in squamo
The incidence of hypercalcemia in squamous cell carcinoma of the head and neck
✍ Dorman, E. B. ;Yang, H. ;Vaughan, C. W. ;Hong, W. K. ;Strong, M. S. πŸ“‚ Article πŸ“… 1984 πŸ› Wiley (John Wiley & Sons) βš– 379 KB πŸ‘ 2 views

Hypercalcemia is a well-recognized phenomenon in squamous cell carcinoma of the head and neck, but the incidence of hypercalcemia in this group of patients is not clear. We have reviewed the records of 166 patients with squamous cell carcinoma of the head and neck presented at the Boston VA Medical

Immunoglobulin allotypes in patients wit
Immunoglobulin allotypes in patients with squamous cell carcinoma of the head and neck
✍ Theodorus Ockhuizen; Janardan P. Pandey; Robert W. Veltri; Myron Arlen; H. Hugh πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 403 KB πŸ‘ 2 views

Gm, A2m, and Km allotypic markers were examined in 40 Caucasian patients with squamous cell carcinomas of the head and neck. Serum IgA levels, the A2m(l) allotypic marker, and antibodies against IgAl, A2m(l), and A2m(2) were measured quantitatively. The frequency of Km(1) was found to be significant